Stockreport

Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses

Celularity Inc. - Class A  (CELU) 
PDF FLORHAM PARK, N.J., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, to [Read more]